BOUL Share Price Performance
Recent BOUL News & Updates
No updates
Boule Diagnostics AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 24, 2025
- Earnings per share (EPS)
- -8.23
- Gross Margin
- 44.84%
- Net Profit Margin
- -61.97%
- Debt/Equity Ratio
- 124.2%
Boule Diagnostics AB (publ) Competitors
About BOUL
- Founded
- 1956
- Employees
- 200
- CEO
- WebsiteView website
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in Spånga, Sweden.
Swedish Market Performance
- 7 Days: -3.5%
- 3 Months: 1.1%
- 1 Year: -0.4%
- Year to Date: -1.5%
Over the last 7 days, the market has dropped 3.5%, driven by pullbacks in every sector, especially the Industrials sector. In the last 12 months the market has been flat overall. Earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading